HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sandra Lassalle Selected Research

Therapeutics

12/2023LKB1-SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition.
12/2023Characterisation of the protein expression of the emerging immunotherapy targets VISTA, LAG-3 and PRAME in primary uveal melanoma: insights from a southern French patient cohort.
6/2023The Need to Set up a Biobank Dedicated to Lymphoid Malignancies: Experience of a Single Center (Laboratory of Clinical and Experimental Pathology, University Côte d'Azur, Nice, France).
5/2023A Real-World Experience from a Single Center (LPCE, Nice, France) Highlights the Urgent Need to Abandon Immunohistochemistry for ROS1 Rearrangement Screening of Advanced Non-Squamous Non-Small Cell Lung Cancer.
4/2022Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).
1/2019The Molecular Pathology of Eye Tumors: A 2019 Update Main Interests for Routine Clinical Practice.
6/2018[Focus on clinical and pathological management of conjunctival melanocytic tumors].
4/2016[Issues and current limits for immunohistochemical assessment of PD-L1 status in bronchial biopsies].
2/2013[Setting up a department of molecular pathology in oncology in a pathology laboratory (LPCE, CHU de Nice)].
4/2010[Role of the surgical pathology laboratory in the pre-analytical approach of molecular biology techniques].
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sandra Lassalle Research Topics

Disease

24Neoplasms (Cancer)
12/2023 - 09/2007
7Melanoma (Melanoma, Malignant)
11/2023 - 05/2015
6Papillary Thyroid Cancer
05/2014 - 11/2009
5Lung Neoplasms (Lung Cancer)
11/2023 - 04/2016
5Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/2023 - 01/2018
5Thyroid Neoplasms (Thyroid Cancer)
05/2016 - 06/2006
4Uveal melanoma
12/2023 - 01/2021
4Adenocarcinoma of Lung
01/2019 - 02/2013
2Neoplasm Metastasis (Metastasis)
12/2021 - 01/2021
1Melanosis (Freckles)
11/2023
1Lymphoma (Lymphomas)
06/2023
1COVID-19
12/2021
1Immune Reconstitution Inflammatory Syndrome
05/2021
1Thyroid Diseases (Thyroid Disease)
01/2021
1Margins of Excision
01/2019
1Pleural Effusion (Pleural Effusions)
01/2018
1Squamous Cell Carcinoma (Epidermoid Carcinoma)
12/2016
1Hypoxia (Hypoxemia)
09/2013
1Colonic Neoplasms (Colon Cancer)
02/2013
1Follicular Adenocarcinoma
10/2011
1Carcinoma (Carcinomatosis)
11/2009
1Hyperplasia
11/2009
1Crohn Disease (Crohn's Disease)
06/2009
1Hand-Foot Syndrome
07/2008
1Gram-Negative Bacterial Infections
09/2007
1Tuberculosis (Tuberculoses)
12/2006
1Granuloma
12/2006
1Acquired Immunodeficiency Syndrome (AIDS)
12/2006
1HIV Infections (HIV Infection)
09/2005
1Lipodystrophy
09/2005

Drug/Important Bio-Agent (IBA)

8Biomarkers (Surrogate Marker)IBA
06/2023 - 03/2018
5Immune Checkpoint InhibitorsIBA
01/2022 - 12/2016
4Formaldehyde (Formol)FDA Link
11/2017 - 12/2006
3Proteins (Proteins, Gene)FDA Link
12/2023 - 01/2010
3Eosine Yellowish-(YS) (Eosin)IBA
11/2023 - 12/2006
3Hematoxylin (Haematoxylon)IBA
11/2023 - 12/2006
3DNA (Deoxyribonucleic Acid)IBA
06/2018 - 12/2006
3ParaffinIBA
11/2017 - 12/2006
3MicroRNAs (MicroRNA)IBA
05/2016 - 10/2011
2MART-1 AntigenIBA
11/2023 - 07/2023
2Indicators and Reagents (Reagents)IBA
12/2021 - 12/2016
2Monoclonal AntibodiesIBA
12/2016 - 05/2015
2Uridine Monophosphate (UMP)IBA
10/2011 - 07/2009
1CalciumIBA
12/2023
1AntioxidantsIBA
12/2023
1Reactive Oxygen Species (Oxygen Radicals)IBA
12/2023
1Immune Checkpoint ProteinsIBA
12/2023
1Proto-Oncogene Proteins c-metIBA
11/2023
1N(1)-methyl-2-lysergic acid diethylamide (MIL)IBA
11/2023
1AntigensIBA
11/2023
1RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA
02/2023
1RNA (Ribonucleic Acid)IBA
01/2021
1Mitomycin (Mitomycin-C)FDA LinkGeneric
01/2019
1Tyrosine Kinase InhibitorsIBA
01/2019
1pembrolizumabIBA
01/2018
1N 30IBA
01/2018
1Mitogen-Activated Protein Kinase Kinases (MEKs)IBA
05/2015
1Mitogen-Activated Protein KinasesIBA
05/2015
1Tissue Inhibitor of Metalloproteinase-1IBA
09/2013
1Carbonic Anhydrase IXIBA
09/2013
1Etoposide (VP 16)FDA LinkGeneric
12/2011
1Lactalbumin (alpha-Lactalbumin)IBA
12/2011
1Histones (Histone)IBA
12/2011
1trichostatin A (A 300)IBA
12/2011
1VorinostatFDA Link
12/2011
1Histone Deacetylase InhibitorsIBA
12/2011
1RacivirIBA
10/2011
1Fixatives (Pickling Agents)IBA
11/2009
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
06/2009
1Capecitabine (Xeloda)FDA Link
07/2008
1Toll-Like Receptors (Toll-Like Receptor)IBA
09/2007

Therapy/Procedure

12Therapeutics
12/2023 - 09/2005
6Immunotherapy
12/2023 - 04/2016
3Highly Active Antiretroviral Therapy (HAART)
05/2021 - 09/2005
1Organ Transplantation
05/2021
1Precision Medicine
01/2021
1Cryotherapy (Therapy, Cold)
12/2019
1Proton Therapy
12/2019
1Molecular Targeted Therapy
02/2019
1Drug Therapy (Chemotherapy)
01/2019
1Lasers (Laser)
12/2006
1Thyroidectomy
06/2006